BACKGROUND: The detection and differentiation of intracardiac masses is still challenging and may include neoplasms and thrombi. The aim of this study was the investigation of a targeted, fibrin-specific contrast agent (EP-2104R) for molecular targeted magnetic resonance imaging (MRI) of left atrial clots. METHODS AND RESULTS: Chronic human thrombi were surgically implanted in the left atrial appendage of 5 swine. Molecular MRI was performed with a navigator-gated, free-breathing, cardiac-triggered 3D inversion-recovery, black-blood, gradient-echo sequence before and after systemic administration of 4 micromol/kg EP-2104R. MR images were analyzed by 2 investigators, and the contrast-to-noise ratio was calculated. Location of clots was confirmed by autopsy, and the gadolinium concentration in the clots was assessed. Before contrast agent administration, thrombi were not visible on black-blood MR images. After contrast administration, all atrial clots (n=5) were selectively visualized as white spots with a high contrast-to-noise ratio (clot/blood, 29.7+/-8.0). The gadolinium concentration in the clots averaged 74+/-45 micromol/L. CONCLUSIONS: The fibrin-specific MR contrast agent EP-2104R allows for selective and high-contrast visualization of left atrial clots by means of molecular targeted MRI.
BACKGROUND: The detection and differentiation of intracardiac masses is still challenging and may include neoplasms and thrombi. The aim of this study was the investigation of a targeted, fibrin-specific contrast agent (EP-2104R) for molecular targeted magnetic resonance imaging (MRI) of left atrial clots. METHODS AND RESULTS: Chronic humanthrombi were surgically implanted in the left atrial appendage of 5 swine. Molecular MRI was performed with a navigator-gated, free-breathing, cardiac-triggered 3D inversion-recovery, black-blood, gradient-echo sequence before and after systemic administration of 4 micromol/kg EP-2104R. MR images were analyzed by 2 investigators, and the contrast-to-noise ratio was calculated. Location of clots was confirmed by autopsy, and the gadolinium concentration in the clots was assessed. Before contrast agent administration, thrombi were not visible on black-blood MR images. After contrast administration, all atrial clots (n=5) were selectively visualized as white spots with a high contrast-to-noise ratio (clot/blood, 29.7+/-8.0). The gadolinium concentration in the clots averaged 74+/-45 micromol/L. CONCLUSIONS: The fibrin-specific MR contrast agent EP-2104R allows for selective and high-contrast visualization of left atrial clots by means of molecular targeted MRI.
Authors: Andrew F Kolodziej; Shrikumar A Nair; Philip Graham; Thomas J McMurry; Robert C Ladner; Charles Wescott; Daniel J Sexton; Peter Caravan Journal: Bioconjug Chem Date: 2012-02-09 Impact factor: 4.774
Authors: René M Botnar; Julia Brangsch; Carolin Reimann; Christian H P Janssen; Reza Razavi; Bernd Hamm; Marcus R Makowski Journal: J Am Heart Assoc Date: 2018-05-30 Impact factor: 5.501
Authors: Ilknur Ay; Francesco Blasi; Tyson A Rietz; Nicholas J Rotile; Sreekanth Kura; Anna Liisa Brownell; Helen Day; Bruno L Oliveira; Richard J Looby; Peter Caravan Journal: Circ Cardiovasc Imaging Date: 2014-04-28 Impact factor: 7.792
Authors: Patrick M Winter; Shelton D Caruthers; Gregory M Lanza; Samuel A Wickline Journal: J Cardiovasc Magn Reson Date: 2010-11-03 Impact factor: 5.364